**Name of Journal:** *World Journal of Experimental Medicine*

**Manuscript NO:** 82105

**Manuscript Type:** LETTER TO THE EDITOR

**Melatonin’s actions are not limited to sleep**

Venaki E *et al*. Melatonin and prolactin

Evangelia Venaki, Eftychia Koukkou, Ioannis Ilias

**Evangelia Venaki,** **Eftychia** **Koukkou,** **Ioannis** **Ilias,** Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, Athens GR-11521, Greece

**Author contributions:** All the authors have collaborated in the conception, research and writing of this contribution.

**Corresponding author: Ioannis Ilias, MD, PhD, Consultant Physician-Scientist,** Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, 2, Elena Venizelou Sq., Athens GR-11521, Greece. iiliasmd@yahoo.com

**Received:** December 5, 2022

**Revised:** January 18, 2023

**Accepted:** February 21, 2023

**Published online:** March 14, 2023

**Abstract**

Melatonin is widely available as a supplement, usually for sleep disorders. The consumption of melatonin supplements has increased considerably in recent years. An overlooked aspect of melatonin’s administration is the resulting increase in prolactin secretion, *via* its action on hypothalamic dopaminergic neurons. We believe that since the effect of melatonin on prolactin is tangible, the laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use. This is an issue that merits further study.

**Key Words:** Melatonin; Sleep; Prolactin; Human; Dopamine; Side-effects

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Venaki E, Koukkou E, Ilias I. Melatonin’s actions are not limited to sleep. *World J Exp Med* 2023; 13(2): 4-6

**URL:** <https://www.wjgnet.com/2220-315x/full/v13/i2/4.htm>

**DOI:** https://dx.doi.org/10.5493/wjem.v13.i2.4

**Core Tip:** Melatonin, although being an active hormone, is widely available as a supplement. The consumption of melatonin supplements has increased considerably in recent years. Melatonin may increase prolactin. The laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use.

**TO THE EDITOR**

Melatonin, although being an active hormone, is widely available as a supplement[1-3]. It is taken to treat sleep disorders/insomnia, for adults usually at doses ranging from 0.5 to 6.0 mg at bedtime, with reported various degrees of effectiveness[4]. Other potential beneficial effects of melatonin include the prevention of delirium in hospitalized patients and - still at the experimental stage - restorative action on the cirrhotic liver[5,6]. Very recently, melatonin, given at 5.0 mg at bedtime in healthy older adults was considered to be effective in increasing sleep time and efficiency[7].

The consumption of melatonin supplements has increased considerably in recent years, as shown in studies in the United Kingdom and the United States[1,2]. In the United States, in the years 1999-2000, 0.4% of the population were taking melatonin, whereas in 2017-2018, this percentage rose to 2.1%[1]. An overlooked aspect of melatonin’s administration is the resulting increase in prolactin secretion, *via* its action on hypothalamic dopaminergic neurons[8,9]. The relevant studies date to the previous century and in the most recent ones, melatonin given at a dose of up to 5 mg at bedtime quadrupled acutely prolactin levels compared to baseline[8,9].

Hyperprolactinemia is not uncommon, especially in women with polycystic ovaries syndrome, pituitary adenomas, hypothyroidism, macroprolactinemia, or therapy with hyperprolactinemia-inducing medications[10]. Interestingly, and despite the known action of melatonin on prolactin, melatonin use is not usually included among the drug-induced causes of hyperprolactinemia[11].

Based on the above, we believe that since the effect of melatonin on prolactin is tangible, the laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use. This issue merits further study, because the caveat is that the available literature has honed on acute effects of melatonin on prolactin. Thus, the effects of chronic use of melatonin on prolactin are obscure. These could be assessed initially in a simple manner: In subjects with hyperprolactinemia, medical history could query on the administration of melatonin. A further step could be a prospective study in subjects that commence melatonin supplementation.

**REFERENCES**

1 **Li J**, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in Use of Melatonin Supplements Among US Adults, 1999-2018. *JAMA* 2022; **327**: 483-485 [PMID: 35103775 DOI: 10.1001/jama.2021.23652]

2 **Wan M**, Begum R, Rashed AN. Trends, geographical variation and factors associated with melatonin prescribing in general practices in England: A practice-level analysis. *Br J Clin Pharmacol* 2022; **88**: 2430-2436 [PMID: 34747044 DOI: 10.1111/bcp.15136]

3 **Grigg-Damberger MM**, Ianakieva D. Poor Quality Control of Over-the-Counter Melatonin: What They Say Is Often Not What You Get. *J Clin Sleep Med* 2017; **13**: 163-165 [PMID: 28095978 DOI: 10.5664/jcsm.6434]

4 **Ferracioli-Oda E**, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. *PLoS One* 2013; **8**: e63773 [PMID: 23691095 DOI: 10.1371/journal.pone.0063773]

5 **Colares JR**, Hartmann RM, Schemitt EG, Fonseca SRB, Brasil MS, Picada JN, Dias AS, Bueno AF, Marroni CA, Marroni NP. Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats. *World J Gastroenterol* 2022; **28**: 348-364 [PMID: 35110954 DOI: 10.3748/wjg.v28.i3.348]

6 **You W**, Fan XY, Lei C, Nie CC, Chen Y, Wang XL. Melatonin intervention to prevent delirium in hospitalized patients: A meta-analysis. *World J Clin Cases* 2022; **10**: 3773-3786 [PMID: 35647160 DOI: 10.12998/wjcc.v10.i12.3773]

7 **Duffy JF**, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. *J Pineal Res* 2022; **73**: e12801 [PMID: 35436355 DOI: 10.1111/jpi.12801]

8 **Forsling ML**, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. *Clin Endocrinol (Oxf)* 1999; **51**: 637-642 [PMID: 10594526 DOI: 10.1046/j.1365-2265.1999.00820.x]

9 **Kostoglou-Athanassiou I**, Treacher DF, Wheeler MJ, Forsling ML. Melatonin administration and pituitary hormone secretion. *Clin Endocrinol (Oxf)* 1998; **48**: 31-37 [PMID: 9509065 DOI: 10.1046/j.1365-2265.1998.00341.x]

10 **Lau CS**, Aw TC. A Current Approach to Hyperprolactinemia. *Int Arch Endocrinol Clin Res* 2019; **5**: 018 [DOI: 10.23937/2572-407X.1510018]

11 **Vilar L**, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. *Neuroendocrinology* 2019; **109**: 7-19 [PMID: 30889571 DOI: 10.1159/000499694]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Hellenic Endocrine Society - Athens Medical Association, 79438.

**Peer-review started:** December 5, 2022

**First decision:** January 17, 2023

**Article in press:** February 21, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Byeon H, South Korea; Menendez-Menendez J, Spain; Oprea VD, Romania **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**